Connection

Michael Hallek to Thalidomide

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Thalidomide.
Michael Hallek
Connection Strength
0.559
Thalidomide
  1. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.559
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.